Clinical Trials Browser

Phase 2 × Irinotecan × NET × Clear all

NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Phase 2 Completed

139 enrolled 14 charts

EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT03963193 2019-05-24

Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type

Phase 2 Unknown

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor